Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hospital of ChinaHKSE:03869 73 EBIT per Share is HK$2.31 as of Dec. 2025. GuruFocus rates HKSE:03869 with a GF Score™ of 73/100 and a GF Value™ of HK$5.52 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Hospital of China ranks better than 62.86% on this metric.
Hospital of China's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$2.31.
During the past 12 months, the average EBIT per Share Growth Rate of Hospital of China was -37.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 20.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -2.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Hospital of China's EBIT per Share or its related term are showing as below:
HKSE:03869'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -19 Med: 8.35 Max: 54.9
Current: 20.9
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Hospital of China was 54.90% per year. The lowest was -19.00% per year. And the median was 8.35% per year.
HKSE:03869's 3-Year EBIT Growth Rate is ranked better than 62.86% of 525
companies
in the Healthcare Providers & Services industry
Industry Median: 11.7
vs HKSE:03869: 20.90
Hospital of China (HKSE:03869) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hospital of China EBIT per Share Related Terms
Hospital of China EBIT per Share Historical Data
* Premium members only.
The historical data trend for Hospital of China's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hospital of China (HKSE:03869) has a EBIT per Share of HK$2.31 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hospital of China and its competitors. According to the industry distribution chart, Hospital of China ranks #195 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 37.1%.
Is Hospital of China's EBIT per Share too high?
Hospital of China's current EBIT per Share is HK$2.31. Based on the distribution chart, Hospital of China ranks #195 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Hospital of China has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hospital of China's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital of China ranks #195 out of 525 companies for EBIT per Share. This puts Hospital of China in the upper half of its industry. The industry median EBIT per Share is 11.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.70, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hospital of China and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital of China's current EBIT per Share is HK$2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital of China stock overvalued right now?
Based on GuruFocus' analysis, Hospital of China (HKSE:03869) is currently considered Possible Value Trap. The stock's GF Value™ is HK$5.52, compared to a current price of HK$3.40 — trading 38.4% below its estimated fair value. The current EBIT per Share is HK$2.31. Hospital of China's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hospital of China (HKSE:03869), the current EBIT per Share is HK$2.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital of China (HKSE:03869) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital of China stock appears to be undervalued.
The current stock price of HK$3.40 is trading 38.4% below its estimated GF Value™ of HK$5.52.
GuruFocus considers Hospital of China to be Possible Value Trap.
Key valuation signals for HKSE:03869:
EBIT per Share: HK$2.31
GF Value™: HK$5.52 vs. price of HK$3.40 (38.4% below fair value)
No single metric tells the full story. See the HKSE:03869 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Corporation of China Ltd is an investment holding company that operates and manages hospitals in the People's Republic of China. In addition to offering hospital management services, it also provides supply chain services, other ancillary services, and sells pharmaceutical products. The company has three operating segments, namely, Hospital management services, General hospital services, and the sale of pharmaceutical products. The General Hospital services segment is the primary revenue generator for the company. All the company's revenue is generates from PRC.
73GF Score
Get the complete analysis for HKSE:03869
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03869 has been successfully added to your 
